FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1602560016> ?p ?o ?g. }

• W1602560016 endingPage "270" @default.
• W1602560016 startingPage "263" @default.
• W1602560016 abstract "Summary. Long-term studies in adults indicate that sustained virologic response (SVR) after combination treatment for chronic hepatitis C (CHC) predicts long-term clearance. Although peginterferon plus ribavirin is now standard care for children with CHC, long-term follow-up studies are not yet available. This study evaluated durability of virologic response over 5 years in children previously treated with interferon alfa-2b plus ribavirin (IFN/R). Ninety-seven of 147 children with CHC, who were treated with IFN/R and completed the 6-month follow-up in two previous clinical trials, participated in this long-term follow-up study. All were assessed annually for up to 5 years; patients with SVR were assessed for durability of virologic response. Children with SVR (n = 56) and those with detectable hepatitis C virus (HCV) RNA 24-week post-treatment (n = 41) were followed for a median of 284 weeks. Overall, 70% (68/97) of patients completed the 5-year follow-up. One patient with genotype 1a CHC had SVR and relapsed at year 1 of follow-up with the same genotype. Kaplan–Meier estimate for sustained response at 5 years was 98% (95% CI: 95%, 100%). Six patients with low-positive HCV RNA levels (n = 4) or missing HCV RNA at the 24-week follow-up visit (n = 2) in the initial treatment studies had virologic response during this long-term follow-up study. Linear growth rate was impaired during treatment with rapid increases in the immediate 6 months post-treatment. Mean height percentile at the end of the 5-year follow-up was slightly less than the mean pretreatment height percentile. Five patients experienced serious adverse events; none related to study drug exposure. SVR after IFN/R predicts long-term clearance of HCV in paediatric patients; growth normalized in the majority of children during the long-term follow-up. Similar long-term results could be expected after peginterferon alfa-2b plus ribavirin treatment." @default.
• W1602560016 created "2016-06-24" @default.
• W1602560016 creator A5000243107 @default.
• W1602560016 creator A5003556153 @default.
• W1602560016 creator A5004741643 @default.
• W1602560016 creator A5006405927 @default.
• W1602560016 creator A5010995241 @default.
• W1602560016 creator A5025247273 @default.
• W1602560016 creator A5025413690 @default.
• W1602560016 creator A5038339390 @default.
• W1602560016 creator A5046466058 @default.
• W1602560016 creator A5053623460 @default.
• W1602560016 creator A5056406094 @default.
• W1602560016 creator A5063561569 @default.
• W1602560016 creator A5066539952 @default.
• W1602560016 creator A5068648022 @default.
• W1602560016 creator A5079795365 @default.
• W1602560016 creator A5081268394 @default.
• W1602560016 creator A5086628652 @default.
• W1602560016 date "2011-11-17" @default.
• W1602560016 modified "2023-09-25" @default.
• W1602560016 title "Durability of sustained response shown in paediatric patients with chronic hepatitis C who were treated with interferon alfa-2b plus ribavirin" @default.
• W1602560016 cites W1969030917 @default.
• W1602560016 cites W1970761895 @default.
• W1602560016 cites W1971011563 @default.
• W1602560016 cites W1979301754 @default.
• W1602560016 cites W1982366903 @default.
• W1602560016 cites W1987986767 @default.
• W1602560016 cites W1988171027 @default.
• W1602560016 cites W1994947695 @default.
• W1602560016 cites W2002437041 @default.
• W1602560016 cites W2005863439 @default.
• W1602560016 cites W2006343970 @default.
• W1602560016 cites W2014927899 @default.
• W1602560016 cites W2020730605 @default.
• W1602560016 cites W2053996087 @default.
• W1602560016 cites W2054433727 @default.
• W1602560016 cites W2054638701 @default.
• W1602560016 cites W2054850951 @default.
• W1602560016 cites W2057407106 @default.
• W1602560016 cites W2064696362 @default.
• W1602560016 cites W2065631609 @default.
• W1602560016 cites W2085197105 @default.
• W1602560016 cites W2092937655 @default.
• W1602560016 cites W2110783625 @default.
• W1602560016 cites W2118620804 @default.
• W1602560016 cites W2133580842 @default.
• W1602560016 cites W2152870084 @default.
• W1602560016 cites W2326890202 @default.
• W1602560016 cites W2371013545 @default.
• W1602560016 cites W2623061205 @default.
• W1602560016 doi "https://doi.org/10.1111/j.1365-2893.2011.01544.x" @default.
• W1602560016 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22404724" @default.
• W1602560016 hasPublicationYear "2011" @default.
• W1602560016 type Work @default.
• W1602560016 sameAs 1602560016 @default.
• W1602560016 citedByCount "12" @default.
• W1602560016 countsByYear W16025600162013 @default.
• W1602560016 countsByYear W16025600162014 @default.
• W1602560016 countsByYear W16025600162015 @default.
• W1602560016 countsByYear W16025600162016 @default.
• W1602560016 countsByYear W16025600162017 @default.
• W1602560016 countsByYear W16025600162018 @default.
• W1602560016 countsByYear W16025600162020 @default.
• W1602560016 crossrefType "journal-article" @default.
• W1602560016 hasAuthorship W1602560016A5000243107 @default.
• W1602560016 hasAuthorship W1602560016A5003556153 @default.
• W1602560016 hasAuthorship W1602560016A5004741643 @default.
• W1602560016 hasAuthorship W1602560016A5006405927 @default.
• W1602560016 hasAuthorship W1602560016A5010995241 @default.
• W1602560016 hasAuthorship W1602560016A5025247273 @default.
• W1602560016 hasAuthorship W1602560016A5025413690 @default.
• W1602560016 hasAuthorship W1602560016A5038339390 @default.
• W1602560016 hasAuthorship W1602560016A5046466058 @default.
• W1602560016 hasAuthorship W1602560016A5053623460 @default.
• W1602560016 hasAuthorship W1602560016A5056406094 @default.
• W1602560016 hasAuthorship W1602560016A5063561569 @default.
• W1602560016 hasAuthorship W1602560016A5066539952 @default.
• W1602560016 hasAuthorship W1602560016A5068648022 @default.
• W1602560016 hasAuthorship W1602560016A5079795365 @default.
• W1602560016 hasAuthorship W1602560016A5081268394 @default.
• W1602560016 hasAuthorship W1602560016A5086628652 @default.
• W1602560016 hasConcept C126322002 @default.
• W1602560016 hasConcept C203014093 @default.
• W1602560016 hasConcept C2522874641 @default.
• W1602560016 hasConcept C2776408679 @default.
• W1602560016 hasConcept C2776455275 @default.
• W1602560016 hasConcept C2780040827 @default.
• W1602560016 hasConcept C71924100 @default.
• W1602560016 hasConcept C90924648 @default.
• W1602560016 hasConceptScore W1602560016C126322002 @default.
• W1602560016 hasConceptScore W1602560016C203014093 @default.
• W1602560016 hasConceptScore W1602560016C2522874641 @default.
• W1602560016 hasConceptScore W1602560016C2776408679 @default.
• W1602560016 hasConceptScore W1602560016C2776455275 @default.
• W1602560016 hasConceptScore W1602560016C2780040827 @default.
• W1602560016 hasConceptScore W1602560016C71924100 @default.
• W1602560016 hasConceptScore W1602560016C90924648 @default.

• next